Oral treatment for diabetes using α-glucosidase inhibitors was a risk factor for chronic obstructive pulmonary disease: a cohort study

doi:doi.org/10.7150/ijms.55361

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/22380

請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/22380

題名:	Oral treatment for diabetes using α-glucosidase inhibitors was a risk factor for chronic obstructive pulmonary disease: a cohort study
作者:	Wu, Sheng-Wen;Ho, Yung-Chyuan;Luo, Ci-Wen;Chen, Hung-Yi;Su, Chun-Hung;Kuan, Yu-Hsiang
關鍵詞:	diabetes mellitus;chronic obstructive pulmonary disease;α-glucosidase inhibitor;cohort study;cox regression
日期:	2021-01-01
上傳時間:	2022-06-06T02:38:36Z (UTC)
出版者:	Ivyspring International Publisher.
摘要:	Objectives: Currently, diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD) have proven to be risk factors for each other. This study aimed to determine the risk relationship between COPD and five common oral medications for DM among patients with DM. Methods: This population-based cohort study was conducted from 2008 to 2013. Patient data were retrieved from the Longitudinal Health Insurance Database (LHID) of the National Health Insurance Research Database (NHIRD). After pairing by gender, age, and index date, time-to-event analysis and multiple regression analysis were performed to determine the factors associated with COPD in patients taking oral medication for DM, including age, gender, income, and comorbidities. We identified 1,028 patients who took oral medication for DM and 1,028 controls who did not take oral medication for DM. Results: We observed that the use of α-glucosidase inhibitors was associated with a higher risk of COPD (hazard ratio [HR]: 1.964, 95% confidence interval [CI]: 1.207-2.380). Furthermore, compared with the control group, α-glucosidase inhibitor users had a higher risk of COPD (HR: 2.295, 95% CI: 1.304-4.038), and no significant difference was observed in other oral medications for DM. Conclusions: Based on present results, we could suggest that patients with DM who used α-glucosidase inhibitors are probably a higher risk of COPD. We recommend that in the future, treatment with α-glucosidase inhibitors upregulate the occurrence of COPD might through gastrointestinal side effects and malnutrition.
URI:	https://ir.csmu.edu.tw:8080/handle/310902500/22380
關聯:	Int J Med Sci, 18(3), 778–784.
顯示於類別:	[醫學系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
v18p0778.pdf		801Kb	Adobe PDF	108	檢視/開啟

檢視Licence

在CSMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....